Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-10-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety, tolerability, and maximum
tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose
(RP2D) of AMG 994 as monotherapy and AMG 994 in combination with AMG 404 in participants with
advanced solid tumors.